Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell

被引:35
作者
Bae, Jooeun
Mitsiades, Constantine
Tai, Yu-Tzu
Bertheau, Robert
Shammas, Masood
Batchu, Ramesh Babu
Li, Cheng
Catley, Lawrence
Prabhala, Rao
Anderson, Kenneth C.
Munshi, Nikhil C.
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA
关键词
D O I
10.4049/jimmunol.178.12.7730
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 90-kDa heat shock protein (Hsp90) plays an important role in conformational regulation of cellular proteins and thereby cellular signaling and function. As Hsp90 is considered a key component of immune function and its inhibition has become an important target for cancer therapy, we here evaluated the role of Hsp90 in human dendritic cell (DQ phenotype and function. Hsp90 inhibition significantly decreased cell surface expression of costimulatory (CD40, CD80, CD86), maturation (CD83), and MHC (HLA-A, B, C and HLA-DP, DQ, DR) markers in immature DC and mature DC and was associated with down-regulation of both RNA and intracellular protein expression. Importantly, Hsp90 inhibition significantly inhibited DC function. It decreased Ag uptake, processing, and presentation by immature DC, leading to reduced T cell proliferation in response to tetanus toxoid as a recall Ag. It also decreased the ability of mature DC to present Ag to T cells and secrete IL-12 as well as induce IFN-gamma secretion by allogeneic T cells. These data therefore demonstrate that Hsp90-mediated protein folding is required for DC function and, conversely, Hsp90 inhibition disrupts the DC function of significant relevance in the setting of clinical trials evaluating novel Hsp90 inhibitor therapy in cancer.
引用
收藏
页码:7730 / 7737
页数:8
相关论文
共 66 条
[1]  
Ahlers JD, 1997, J IMMUNOL, V158, P3947
[2]   A ROLE FOR HSP90 IN CELL-CYCLE CONTROL - WEE1 TYROSINE KINASE-ACTIVITY REQUIRES INTERACTION WITH HSP90 [J].
ALIGUE, R ;
AKHAVANNIAK, H ;
RUSSELL, P .
EMBO JOURNAL, 1994, 13 (24) :6099-6106
[3]  
An WG, 2000, CELL GROWTH DIFFER, V11, P355
[4]  
Bagatell R, 2004, MOL CANCER THER, V3, P1021
[5]   The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future [J].
Banerji, Udai ;
Judson, Ian ;
Workman, Paul .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :385-390
[6]   Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 [J].
Basso, AD ;
Solit, DB ;
Munster, PN ;
Rosen, N .
ONCOGENE, 2002, 21 (08) :1159-1166
[7]  
Batchu RB, 2002, CANCER RES, V62, P2982
[8]   Hsp90: an emerging target for breast cancer therapy [J].
Beliakoff, J ;
Whitesell, L .
ANTI-CANCER DRUGS, 2004, 15 (07) :651-662
[9]   Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules [J].
Binder, RJ ;
Blachere, NE ;
Srivastava, PK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) :17163-17171
[10]  
BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933